TABLE 3.

Leukocytes in bronchoalveolar lavage fluid of virus-infected mice^a

Day	Leukocytes (102)/ml of BAL fluid ± SE
	No Met-RANTES		Met-RANTES (10 μg/day)		Met-RANTES (100 μg/day)		CCR1−/− mice
	+pbs	+ribavirin	+pbs	+ribavirin	+pbs	+ribavirin
3	3.3 ± 0.3	2.3 ± 0.6	1.8 ± 0.3	2.0 ± 0.5	0.8 ± 0.01	0.6 ± 0.01	0.3 ± 0.04
5	4,960 ± 270	3,770 ± 300	535 ± 48* [9.3]	486 ± 55* [7.7]	87 ± 9** [57]	99 ± 21** [38]	0.5 ± 0.1 [9,900]**
7	5,970 ± 480	5,080 ± 410	1,040 ± 75* [5.7]	1,220 ± 100* [4.2]	210 ± 23** [28]	265 ± 48** [19]	1.4 ± 0.3 [4,300]**
10	3,560 ± 250	4,670 ± 370	810 ± 44* [4.3]	990 ± 30* [4.8]	185 ± 39** [19]	175 ± 30** [27]	1.0 ± 0.5 [3,600]**

^aBronchoalveolar lavage (BAL) fluids were harvested from PVM-infected wild-type mice treated with ribavirin (75 mg/kg/day) or control (pbs) and/or Met-RANTES or CCR1 −/− mice (untreated) on days postinoculation as indicated. All treatments were initiated on day 3 postinoculation. Data are presented as mean ± SE; *P < 0.05 compared to +pbs or +ribavirin alone controls, respectively; **P < 0.05 compared to +pbs +Met-RANTES (10 μg/day) or +ribavirin +Met-RANTES +(10 μg/day) groups, respectively, n = 3 mice per data point. Fold reduction (vs. no Met-RANTES at same time point) is shown in brackets.